Dr. Catherine M. Broome, MD

Dr. Broome practices at Medstar Georgetown Medical Center in Washington, District of Columbia.

Dr. Broome's NPI, 1669470985, was assigned on July 11, 2005. Dr. Broome graduated from Louisiana State University School of Medicine in Shreveport in 1985. Dr. Broome holds District of Columbia license MD037292.

Dr. Broome's primary practice is Medstar Georgetown Medical Center, at 3800 Reservoir NW Rd, Washington, DC 20007 in District Of Columbia County. The practice phone is (202) 444-1400.

Dr. Broome's primary practice is Medstar Georgetown Medical Center in Washington, District of Columbia. Dr. Broome is also affiliated with MedStar Georgetown University Hospital. The medical group on file is MedStar Medical Group. Dmand AI also links Dr. Broome to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Broome practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Broome's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Broome is licensed in District of Columbia.

CMS data shows 461 Medicare services from Dr. Broome across 6 procedure codes in 2024, for 235 Medicare patients. Medicare paid $43,426 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 235 Medicare patients who saw Dr. Broome in 2024. The largest group is 65 to 74, with 101 patients. 73% of them have high blood pressure, and 73% have high cholesterol. 12% are also on Medicaid. Their average risk score is 1.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Broome's median patient age at 48, with 57% women.

In 2024, Dr. Broome wrote 475 Medicare Part D claims for 80 patients. CMS names the drug for 348 of them, across 11 drugs with 11 or more claims each, at $2,922,367 in total drug cost. In 2023, CMS named 278 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Broome for performance year 2024, reported as part of a group. Dr. Broome accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 27 papers to Dr. Broome, published from 2017 to 2025. 2024 was the busiest year, with 5. The most frequent topics are Anemia, Hemolytic, Autoimmune, Antibodies, Monoclonal, Humanized and Purpura, Thrombocytopenic, Idiopathic. Dr. Broome has published most often in Am J Hematol. Dr. Broome's most frequent co-authors are David John Kuter, MD, Ilene C. Weitz, MD and David F. Cella, PhD.

Dmand AI links Dr. Broome to 10 clinical trials, 4 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Anemia, Hemolytic, Autoimmune, Anemia, Hemolytic and Anemia, Aplastic. Bioverativ, a Sanofi company sponsors the most, 3. Open Payments lists research payments to Dr. Broome that name 4 trials.

CMS Open Payments shows 431 general payments to Dr. Broome from 12 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 50% of the total. Alexion Pharmaceuticals, Inc. paid the most, $247,261. It also lists 37 research payments totaling $248,309 from 2018 to 2025, naming 4 clinical trials.

Dr. Broome graduated from Louisiana State University School of Medicine in Shreveport in 1985.